Published On: Thu, Sep 22nd, 2016

Investment Analysts’ Weekly Ratings Changes for Novavax (NVAX)

A number of firms have modified their ratings and price targets on shares of Novavax (NASDAQ: NVAX) recently:

9/21/2016 – Novavax was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
9/20/2016 – Novavax had its price target lowered by analysts at Chardan Capital from $5.75 to $1.50. They now have a “neutral” rating on the stock.
9/16/2016 – Novavax was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating. They now have a $2.00 price target on the stock, down previously from $14.00.
9/16/2016 – Novavax had its price target lowered by analysts at FBR & Co from $17.00 to $12.00. They now have an “outperform” rating on the stock.
9/16/2016 – Novavax was downgraded by analysts at Ladenburg Thalmann from a “buy” rating to a “neutral” rating.
9/16/2016 – Novavax was downgraded by analysts at Piper Jaffray Cos. from an “overweight” rating to a “neutral” rating. They now have a $1.00 price target on the stock, down previously from $14.00. They wrote, “So, Now What?”
9/16/2016 – Novavax was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
9/16/2016 – Novavax was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $1.50 price target on the stock, down previously from $12.00.
9/16/2016 – Novavax had its price target lowered by analysts at S&P Equity Research from $1.44 to $1.17.
9/9/2016 – Novavax had its “overweight” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $14.00 price target on the stock.
8/29/2016 – Novavax had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $25.00 price target on the stock.
8/23/2016 – Novavax was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $8.66 price target on the stock.
8/15/2016 – Novavax was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $7.86 price target on the stock.
8/14/2016 – Novavax had its “hold” rating reaffirmed by analysts at Chardan Capital. They now have a $5.75 price target on the stock.
8/11/2016 – Novavax was given a new $17.00 price target on by analysts at FBR & Co. They now have a “buy” rating on the stock.
8/10/2016 – Novavax was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
8/9/2016 – Novavax was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $7.86 price target on the stock.
7/28/2016 – Novavax had its price target raised by analysts at Citigroup Inc. from $10.00 to $12.00. They now have a “buy” rating on the stock.
7/27/2016 – Novavax had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
7/25/2016 – Novavax was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $7.77 price target on the stock.

Shares of Novavax Inc. (NASDAQ:NVAX) traded up 10.82% during mid-day trading on Thursday, reaching $2.15. 84,704,307 shares of the company traded hands. The firm has a 50-day moving average price of $6.69 and a 200 day moving average price of $6.16. Novavax Inc. has a 52 week low of $1.16 and a 52 week high of $9.56. The firm’s market capitalization is $582.29 million.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.04. Novavax had a negative return on equity of 112.45% and a negative net margin of 1,405.84%. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $8.03 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. The business’s quarterly revenue was down 82.1% compared to the same quarter last year. On average, analysts anticipate that Novavax Inc. will post ($1.09) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/investment-analysts-weekly-ratings-changes-for-novavax-nvax.html

In related news, Director Gail Boudreaux purchased 100,000 shares of the business’s stock in a transaction dated Tuesday, September 20th. The stock was acquired at an average price of $1.45 per share, for a total transaction of $145,000.00. Following the completion of the purchase, the director now directly owns 200,000 shares of the company’s stock, valued at $290,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 3.50% of the stock is owned by corporate insiders.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novavax Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>